Assesment, treatment and prevention of atypical hemolytic uremic syndrome

International Journal of Preventive Medicine

Volumn 4, Issue 1, 2013, Pages 6-14

  Nickavar, Azar ^a   Sotoudeh, Kambiz ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Atypical hemolytic uremic syndrome; Children; Pathogenesis; Prevention; Treatment

Indexed keywords

ALTERNATIVE COMPLEMENT PATHWAY C3 C5 CONVERTASE; BLEOMYCIN; CALCINEURIN INHIBITOR; CISPLATIN; CLOPIDOGREL; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C3B RECEPTOR; COMPLEMENT COMPONENT C4 BINDING PROTEIN; COMPLEMENT FACTOR H; COMPLEMENT FACTOR I; CYANOCOBALAMIN; CYCLOSPORIN; ECULIZUMAB; FRESH FROZEN PLASMA; GEMCITABINE; INTERFERON; MEMBRANE COFACTOR PROTEIN; MITOMYCIN; OKT 3; PEXELIZUMAB; PHOSPHOLIPID ANTIBODY; PROPERDIN; QUININE; STEROID; TACROLIMUS; THROMBOMODULIN; TICLOPIDINE; UNINDEXED DRUG; VON WILLEBRAND FACTOR; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ANTIPHOSPHOLIPID SYNDROME; ARTICLE; BLOOD TRANSFUSION; CLINICAL FEATURE; COMPLEMENT DISORDER; DIARRHEA; GENE MUTATION; GENOTYPE PHENOTYPE CORRELATION; GRAFT SURVIVAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMODIALYSIS; HEMOLYTIC UREMIC SYNDROME; HEREDITY; HUMAN; INBORN ERROR OF METABOLISM; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; MEDICAL ASSESSMENT; NEPHRECTOMY; PATHOGENESIS; PATIENT CARE; PERITONEAL DIALYSIS; PLASMAPHERESIS; PREGNANCY; PROGNOSIS; PROSTATE ADENOCARCINOMA; RECURRENCE RISK; RECURRENT DISEASE; RISK FACTOR; SCLERODERMA; SPLENECTOMY; STOMACH ADENOCARCINOMA; SYSTEMATIC REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA;

EID: 84874777659     PISSN: 20087802     EISSN: 20088213     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Goicoechea de Jorge E, Harris CL, Esparza-Gordillo J, Carreras L, Arranz EA, Garrido CA, et al. Gain-of-function mutations in complement factor B are associated with atypical hemolytic uremic syndrome. Proc Natl Acad Sci USA 2007;104:240-5.
2. Zimmerhackl LB, Scheiring J, Prüfer F, Taylor CM, Loirat C. Renal transplantation in HUS patients with disorders of complement regulation. Pediatr Nephrol 2007;22:10-6.
3. Jokiranta TS, Zipfel PF, Fremeaux-Bacchi V, Taylor CM, Goodship TJ, Noris M. Where next with atypical hemolytic uremic syndrome? Mol Immunol 2007;44:3889-900.
4. Zimmerhackl LB, Besbas N, Jungraithmayr T, van de Kar N, Karch H, Karpman D, et al. Epidemiology, clinical presentation, and pathophysiology of atypical and recurrent hemolytic uremic syndrome. Semin Thromb Hemost 2006;32:113-20.
5. Kavanagh D, Richards A, Atkinson J. Complement regulatory genes and hemolytic uremic syndromes. Annu Rev Med 2008;59:293-309.
6. Trachtman H. Introduction: Education teaching article series on hemolytic uremic syndrome. Pediatr Nephrol 2008;23:1423-4.
7. Noris M, Remuzzi G. Hemolytic uremic syndrome. J Am Soc Nephrol 2005;16:1035-50.
8. Scheiring J, Rosales A, Zimmerhackl LB. Clinical practice. Today's understanding of the haemolytic uraemic syndrome. Eur J Pediatr 2010;169:7-13.
9. Kavanagh D, Goodship TH, Richards A. Atypical haemolytic uraemic syndrome. Br Med Bull 2006;77-78:5-22.
10. Constantinescu AR, Bitzan M, Weiss LS, Christen E, Kaplan BS, Cnaan A, et al. Non-enteropathic hemolytic uremic syndrome: Causes and short-term course. Am J Kidney Dis 2004;43:976-82.
11. Amirlak I, Amirlak B. Haemolytic uraemic syndrome: An overview. Nephrology (Carlton) 2006;11:213-8.
12. Loirat C, Noris M, Fremeaux-Bacchi V. Complement and the atypical hemolytic uremic syndrome in children. Pediatr Nephrol 2008;23:1957-72.
13. Tsukamoto H, Horiuchi T. Clinical aspects of the complement system. Rinsho Byori 2006;54:757-62.
14. Kavanagh D, Goodship TH. Update on evaluating complement in hemolytic uremic syndrome. Curr Opin Nephrol Hypertens 2007;16:565-71.
15. Johnson S, Taylor CM. What's new in haemolytic uraemic syndrome? Eur J Pediatr 2008;167:965-71.
16. Ståhl AL, Vaziri-Sani F, Heinen S, Kristoffersson AC, Gydell KH, Raafat R, et al. Factor H dysfunction in patients with atypical hemolytic uremic syndrome contributes to complement deposition on platelets and their activation. Blood 2008;111:5307-15.
17. Lang PA, Beringer O, Nicolay JP, Amon O, Kempe DS, Hermle T, et al. Suicidal death of erythrocytes in recurrent hemolytic uremic syndrome. J Mol Med (Berl) 2006;84:378-88.
18. Kavanagh D, Richards A, Fremeaux-Bacchi V, Noris M, Goodship T, Remuzzi G, et al. Screening for complement system abnormalities in patients with atypical hemolytic uremic syndrome. Clin J Am Soc Nephrol 2007;2:591-6.
19. Sellier-Leclerc A L, Fremeaux-Bacchi V, Dragon-Durey MA, Macher MA, Niaudet P, Guest G, et al. Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome. J Am Soc Nephrol 2007;18:2392-400.
20. Ault BH. Factor H and the pathogenesis of renal diseases. Pediatr Nephrol 2000;14:1045-53.
21. Cho HY, Lee BS, Moon KC, Ha IS, Cheong HI, Choi Y. Complete factor H deficiency-associated atypical hemolytic uremic syndrome in a neonate. Pediatr Nephrol 2007;22:874-80.
22. Sethi SK, Marie-Agnes DD, Thaker N, Hari P, Bagga A. Hemolytic uremic syndrome due to homozygous factor H deficiency. Clin Exp Nephrol 2009;13:526-30.
23. Goodship TH. Factor H genotype-phenotype correlations: Lessons from aHUS, MPGN II, and AMD. Kidney Int 2006;70:12-3.
24. Józsi M, Strobel S, Dahse HM, Liu WS, Hoyer PF, Oppermann M, et al. Anti factor H autoantibodies block C-terminal recognition function of factor H in hemolytic uremic syndrome. Blood 2007;110:1516-8.
25. Richards A, Kathryn Liszewski M, Kavanagh D, Fang CJ, Moulton E, Fremeaux-Bacchi V, et al. Implications of the initial mutations in membrane cofactor protein (MCP; CD46) leading to atypical hemolytic uremic syndrome. Mol Immunol 2007;44:111-22.
26. Zipfel PF, Edey M, Heinen S, Józsi M, Richter H, Misselwitz J, et al. Deletion of complement factor H-related genes CFHR1 and CFHR3 is associated with atypical hemolytic uremic syndrome. PLoS Genet 2007;3:e41.
27. Lee BH, Kwak SH, Shin JI, Lee SH, Choi HJ, Kang HG, et al. Atypical hemolytic uremic syndrome associated with complement factor H autoantibodies and CFHR1/ CFHR3 deficiency. Pediatr Res 2009;66:336-40.
28. Lhotta K, Janecke AR, Scheiring J, Petzlberger B, Giner T, Fally V, et al. A large family with a gain-of-function mutation of complement C3 predisposing to atypical hemolytic uremic syndrome, microhematuria, hypertension and chronic renal failure. Clin J Am Soc Nephrol 2009;4:1356-62.
29. Delvaeye M, Noris M, De Vriese A, Esmon CT, Esmon NL, Ferrell G, et al. Thrombomodulin mutations in atypical hemolytic-uremic syndrome. N Engl J Med 2009;361:345-57.
30. Cruzado JM, de Córdoba SR, Melilli E, Bestard O, Rama I, Sánchez-Corral P, López-Trascasa M, et al. Successful renal transplantation in a patient with atypical hemolytic uremic syndrome carrying mutations in both factor I and MCP. Am J Transplant 2009;9:1477-83.
31. Lapeyraque AL, Wagner E, Phan V, Clermont MJ, Merouani A, Frémeaux-Bacchi V, et al. Efficacy of plasma therapy in atypical hemolytic uremic syndrome with complement factor H mutations. Pediatr Nephrol 2008;23:1363-6.
32. th ed. Philadelphia: Lippincott Williams and Wilkins; 2007. p. 275-99.
33. Watt T, Warshaw B, Katzenstein HM. Atypical hemolytic uremic syndrome responsive to steroids and intravenous immune globulin. Pediatr Blood Cancer 2009;53:90-1.
34. Davin JC, Strain L, Goodship TH. Plasma therapy in atypical haemolytic uremic syndrome: Lessons from a family with a factor H mutation. Pediatr Nephrol 2008;23:1517-21.
35. Zimmerhackl LB, Hofer J, Cortina G, Mark W, Würzner R, Jungraithmayr TC, et al. Prophylactic eculizumab after renal transplantation in atypical hemolytic-uremic syndrome. N Engl J Med 2010;362:1746-8.
36. Nester C, Stewart Z, Myers D, Jetton J, Nair R, Reed A, et al. Pre-emptive eculizumab and plasmapheresis for renal transplant in atypical hemolytic uremic syndrome. Clin J Am Soc Nephrol 2011;6:1488-94.